Twice the benefits with twincretins?

Affiliations

¹ Universitätsklinikum Leipzig and Helmholtz Institut für Metabolismus, Adipositas und Gefäßforschung (HI-MAG), Leipzig, Germany.
² Helmholtz Zentrum München, Neuherberg, Germany; Technische Universität München, Munich 80333, Germany. Electronic address: matthias.tschoep@helmholtz-muenchen.de.

Comment

Michael Stumvoll et al. Lancet. 2018.

. 2018 Nov 17;392(10160):2142-2144.

doi: 10.1016/S0140-6736(18)32466-8. Epub 2018 Oct 4.

¹ Universitätsklinikum Leipzig and Helmholtz Institut für Metabolismus, Adipositas und Gefäßforschung (HI-MAG), Leipzig, Germany.
² Helmholtz Zentrum München, Neuherberg, Germany; Technische Universität München, Munich 80333, Germany. Electronic address: matthias.tschoep@helmholtz-muenchen.de.

No abstract available

Comment on

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Frias JP, et al. Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293770 Clinical Trial.